Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) has experienced a rise in its stock price by 0.44 compared to its previous closing price of 4.59. However, the company has seen a gain of 30.59% in its stock price over the last five trading days. businesswire.com reported 2024-11-26 that BOSTON–(BUSINESS WIRE)–Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that management will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024 at 12:30 p.m. ET at the Lotte New York Palace. A live webcast of Ironwood’s fireside chat will be accessible through the Investors section of the company’s website at www.ironwoodpharma.com. A replay of the webcast will be available on Ironwood’s website following the confe.
Is It Worth Investing in Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) Right Now?
The 36-month beta value for IRWD is also noteworthy at 0.36. There are mixed opinions on the stock, with 3 analysts rating it as a “buy,” 2 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for IRWD is 155.77M, and at present, short sellers hold a 7.76% of that float. The average trading volume of IRWD on December 26, 2024 was 1.76M shares.
IRWD’s Market Performance
IRWD stock saw an increase of 30.59% in the past week, with a monthly gain of 34.01% and a quarterly increase of 17.30%. The volatility ratio for the week is 14.19%, and the volatility levels for the last 30 days are 10.05% for Ironwood Pharmaceuticals Inc (IRWD). The simple moving average for the last 20 days is 23.53% for IRWD’s stock, with a simple moving average of -19.48% for the last 200 days.
Analysts’ Opinion of IRWD
Many brokerage firms have already submitted their reports for IRWD stocks, with Leerink Partners repeating the rating for IRWD by listing it as a “Market Perform.” The predicted price for IRWD in the upcoming period, according to Leerink Partners is $5 based on the research report published on September 09, 2024 of the current year 2024.
CapitalOne, on the other hand, stated in their research note that they expect to see IRWD reach a price target of $4, previously predicting the price at $12. The rating they have provided for IRWD stocks is “Equal Weight” according to the report published on August 08th, 2024.
Craig Hallum gave a rating of “Buy” to IRWD, setting the target price at $21 in the report published on January 17th of the current year.
IRWD Trading at 15.32% from the 50-Day Moving Average
After a stumble in the market that brought IRWD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -70.64% of loss for the given period.
Volatility was left at 10.05%, however, over the last 30 days, the volatility rate increased by 14.19%, as shares surge +37.61% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +7.46% upper at present.
During the last 5 trading sessions, IRWD rose by +30.59%, which changed the moving average for the period of 200-days by -48.49% in comparison to the 20-day moving average, which settled at $3.73. In addition, Ironwood Pharmaceuticals Inc saw -59.70% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at IRWD starting from Davis Andrew, who sale 5,360 shares at the price of $4.08 back on Nov 18 ’24. After this action, Davis Andrew now owns 284,685 shares of Ironwood Pharmaceuticals Inc, valued at $21,869 using the latest closing price.
Emany Sravan Kumar, the SVP, COO and CFO of Ironwood Pharmaceuticals Inc, sale 11,001 shares at $4.08 during a trade that took place back on Nov 18 ’24, which means that Emany Sravan Kumar is holding 309,572 shares at $44,884 based on the most recent closing price.
Stock Fundamentals for IRWD
Current profitability levels for the company are sitting at:
- 0.29 for the present operating margin
- 1.0 for the gross margin
The net margin for Ironwood Pharmaceuticals Inc stands at 0.07. The total capital return value is set at 0.32. Equity return is now at value -559.14, with -0.54 for asset returns.
Based on Ironwood Pharmaceuticals Inc (IRWD), the company’s capital structure generated 2.08 points at debt to capital in total, while cash flow to debt ratio is standing at 0.21. The debt to equity ratio resting at -1.92. The interest coverage ratio of the stock is 3.38.
Currently, EBITDA for the company is -924.86 million with net debt to EBITDA at 4.96. When we switch over and look at the enterprise to sales, we see a ratio of 3.34. The receivables turnover for the company is 4.97for trailing twelve months and the total asset turnover is 0.97. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.62.
Conclusion
In summary, Ironwood Pharmaceuticals Inc (IRWD) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
